Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Charles River Laboratories International, Inc. (CRL) trades at a EV/Sales of 4.2×. Over the past ten years it has ranged from 1.8× (April 2025) to 7.8× (September 2021); the current reading is higher than 85% of that period. That is below the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 2.9× 3.30%
FY2024 2.8× (18.19%)
FY2023 3.5× 1.96%
FY2022 3.4× (43.55%)
FY2021 6.0× 25.12%
FY2020 4.8× 39.31%
FY2019 3.5× 13.96%
FY2018 3.0× (9.30%)
FY2017 3.4× 19.69%
FY2016 2.8× (14.72%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 3.3× 22.87%
Mar 2026 2.7× (7.84%)
Dec 2025 2.9× 22.27%
Sep 2025 2.4× 0.86%
42 more quarters

Against its own ten years

Low 1.8× High 7.8×
Ten-year median 3.3×
Current reading's percentile 83

EV/Sales against peers

Company EV/Sales
ICLR ICON PLC compare 1.9×
LH Labcorp Holdings Inc. compare 2.2×
DGX Quest Diagnostics Incorporated compare 2.7×
CRL Charles River Laboratories International, Inc. 4.2×
QGEN QIAGEN N.V. compare 4.9×
MEDP Medpace Holdings, Inc. compare 6.1×
RVTY Revvity Inc. compare 6.6×
GH Guardant Health, Inc. compare 18.2×
TWST Twist Bioscience Corporation compare 18.8×
Diagnostics & Research industry median 5.5×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CRL